Is this GLP-1.2? New generation of weight-loss drugs moving in
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials testing whether it can be used for overweight or obesity. It is injectable and, according to Nature, the estimated year of its US approval is 2026.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Physicians need to meet patients ‘where they are’ to develop a comprehensive plan to keep weight off and live a healthy ...
RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...
One such revolutionary approach is the TMates GLP-1 weight loss program. TMates is a comprehensive, doctor-approved weight loss service that provides medically supervised weight loss ...
Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President Trump’s tariffs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback